Some individuals transition to semaglutide for cost reasons or better insurance coverage
J Cereb Blood Flow Metab 31(8):16961705 Perry T, Holloway HW, Weerasuriya A, Mouton PR, Duffy K, Mattison JA, Greig NH (2007) Evidence of GLP-1-mediated neuroprotection in an animal model of pyridoxine-induced peripheral sensory neuropathy
If low energy is the reason you are looking beyond GLP-1 medication, start by asking what is causing it: lower intake, dehydration, a possible nutrient gap, or the dose adjustment itself
This is particularly true if they are also com- plaining of muscle tenderness or other musculoskeletal symptoms
These explanations are speculative in nature and future research may dig deeper in the origin of the relationship among these neurometabolites